November 21, 2012 8:01 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Rexahn Pharmaceuticals, Inc. (NYSE: RNN), a clinical stage pharmaceuticalcompany dedicated to developing and commercializing first-in-class oncologytherapeutics, today announced that it has been issued a United States patent(No. 8,314,100), titled “1-[6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero) arylpiperazine derivatives.”This new patent covers Rexahn's quinoxalinyl-piperazine compounds, the processfor the preparation of such compounds and their pharmaceutical composition.The patent includes Rexahn's RX-5902, a first-in-class p68 helicase inhibitor,that is an orally available new chemical entity exhibiting potent antitumorproperties in several types of tumors. RX-5902 has also shown to possessstrong anti-proliferative activity against known anti-cancer drug-resistantcancer cells, and a synergistic effect with known anti-cancer drugs.Rexahn has previously been awarded patents for quinoxalinyl-piperazinecompounds in Europe, Australia, Canada and Mexico.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.